Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
| Revenue (TTM) | $2.23B |
| Gross Profit (TTM) | $-1.47B |
| EBITDA | $-2.20B |
| Operating Margin | -558.00% |
| Return on Equity | -39.00% |
| Return on Assets | -13.30% |
| Revenue/Share (TTM) | $5.66 |
| Book Value | $21.95 |
| Price-to-Book | 14.26 |
| Price-to-Sales (TTM) | 45.55 |
| EV/Revenue | 41.88 |
| EV/EBITDA | 4.64 |
| Quarterly Earnings Growth (YoY) | -85.10% |
| Quarterly Revenue Growth (YoY) | 2.10% |
| Shares Outstanding | $399.24M |
| Float | $371.98M |
| % Insiders | 7.36% |
| % Institutions | 80.45% |
Volatility is currently contracting
Moderna stock has surged as much as 10% in Friday's trading session, reaching a fresh 52-week high after delivering much stronger-than-expected Q3 results.
Moderna's Q3 earnings beat estimates on strong COVID-19 vaccine sales, returning to profitability and boosting its 2026 revenue growth outlook.
GSK, Moderna settle patent dispute over Moderna COVID, RSV shots
Revenue jumped 29% on international COVID vaccine sales tied to long-term government deals. Moderna raised its 2026 revenue growth outlook to 15% to 25%.
BLS results were far better than expected: +165K, close to triple the +59K analysts were looking for.
Moderna NASDAQ: MRNA raised its 2026 revenue growth outlook after reporting higher third-quarter sales and a return to quarterly profitability, as demand for its COVID-19 vaccines and international partnerships supported results.
A quarter that produced a surprise profit and a bigger 2026 forecast is sending Moderna (NASDAQ:MRNA | MRNA Price Prediction) higher again. Moderna stock is at $254.07 in morning trading, up 5%.
Moderna (NASDAQ:MRNA) stock was last seen up 3.9% to trade at $250.95 after reporting third-quarter earnings of $0.38 per share on $1.3 billion in revenue, versus Wall Street estimates of a loss of $1.25 per share on roughly $882 million in revenue.
Moderna earned a surprise profit in the third quarter, while analysts expected a loss of more than $1 per share. Management raised its full-year revenue growth outlook to 15% to 25% and cut its R&D budget.
Moderna (MRNA) came out with quarterly earnings of $0.38 per share, beating the Zacks Consensus Estimate of a loss of $1.1 per share. This compares to a loss of $0.51 per share a year ago.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on MRNA and any ticker you trade — then tracks every position and per-strategy win rate.
